Now showing items 1-8 of 8

  • Urbanucci, Alfonso; Barfeld, Stefan Jörg; Kytölä, Ville; Itkonen, Harri; Coleman, Ilsa M.; Vodák, Daniel; Sjöblom, Liisa; Sheng, Xia; Minner, Sarah; Burdelski, Christoph; Kivinummi, Kati K.; Kohvakka, Annika; Kregel, Steven; Takhar, Mandeep; Alshalalfa, Mohammed; Davicioni, Elai; Erho, Nicholas; Lloyd, Paul; Karnes, R. Jeffrey; Ross, Ashley E.; Schaeffer, Edward M.; Vander Griend, Donald J; Knapp, Stefan; Corey, Eva; Feng, Felix Y.; Nelson, Peter S.; Saatcioglu, Fahri; Knudsen, Karen E.; Tammela, Teuvo L.J.; Sauter, Guido; Schlomm, Thorsten; Nykter, Matti; Visakorpi, Tapio; Mills, Ian Geoffrey (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2017)
    Global changes in chromatin accessibility may drive cancer progression by reprogramming transcription factor (TF) binding. In addition, histone acetylation readers such as bromodomain-containing protein 4 (BRD4) have been ...
  • Urbanucci, Alfonso; Mills, Ian Geoffrey (Journal article / Tidsskriftartikkel / AcceptedVersion; Peer reviewed, 2018)
    Several oncogenic factors have been involved in prostate cancer progression. However, therapeutic approaches still focus on suppression of androgen receptor (AR) signaling. In fact, whereas the full-length AR incorporates ...
  • Tekpli, Xavier; Urbanucci, Alfonso; Hashim, Adnan; Vågbø, Cathrine B; Lyle, Robert; Kringen, Marianne K; Staff, Anne C; Dybedal, Ingunn; Mills, Ian G; Klungland, Arne; Staerk, Judith (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2016)
    Background Hematopoietic stem cell renewal and differentiation are regulated through epigenetic processes. The conversion of 5-methylcytosine into 5-hydroxymethylcytosine (5hmC) by ten-eleven-translocation ...
  • Khanna, Anchit; Rane, Jayant K.; Kivinummi, Kati K.; Urbanucci, Alfonso; Helenius, Merja A.; Tolonen, Teemu T.; Saramäki, Outi R.; Latonen, Leena; Manni, Visa; Pimanda, John E.; Maitland, Norman J.; Westermarck, Jukka; Visakorpi, Tapio (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2015)
    Residual androgen receptor (AR)-signaling and presence of cancer stem-like cells (SCs) are the two emerging paradigms for clinically challenging castration-resistant prostate cancer (CRPC). Therefore, identification of ...
  • Handle, Florian; Prekovic, Stefan; Helsen, Christine; van den Broeck, Thomas; Smeets, Elien; Moris, Lisa; Eerlings, Roy; El Kharraz, Sarah; Urbanucci, Alfonso; Mills, Ian Geoffrey; Joniau, Steven; Attard, Gerhardt; Claessens, Frank (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2019)
    Inhibition of the androgen receptor (AR) by second-generation anti-androgens is a standard treatment for metastatic castration resistant prostate cancer (mCRPC), but it inevitably leads to the development of resistance. ...
  • Itkonen, Harri; Urbanucci, Alfonso; Sara ES, Martin; Khan, Aziz; Mathelier, Anthony; Thiede, Bernd; Walker, Suzanne; Mills, Ian Geoffrey (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2019)
    O-GlcNAc transferase (OGT) is overexpressed in aggressive prostate cancer. OGT modifies intra-cellular proteins via single sugar conjugation (O-GlcNAcylation) to alter their activity. We recently discovered the first ...
  • Barfeld, Stefan J.; Fazli, Ladan; Persson, Margareta; Marjavaara, Lisette; Urbanucci, Alfonso; Kaukoniemi, Kirsi M.; Rennie, Paul S.; Ceder, Yvonne; Chabes, Andrei; Visakorpi, Tapio; Mills, Ian G. (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2015)
    The androgen receptor is a key transcription factor contributing to the development of all stages of prostate cancer (PCa). In addition, other transcription factors have been associated with poor prognosis in PCa, amongst ...
  • Lund, Kaja; Dembinski, Jennifer Lynn; Solberg, Nina; Urbanucci, Alfonso; Mills, Ian Geoffrey; Krauss, Stefan (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2015)
    Background Pancreatic adenocarcinoma is a lethal disease with 5-year survival of less than 5%. 5-fluorouracil (5-FU) is a principal first-line therapy, but treatment only extends survival modestly and is seldom curative. ...